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Background: Exendin-4, an exogenous glucagon-like peptide-1 receptor (GLP-1R) agonist, protects the heart from
ischemia/reperfusion injury. However, the mechanisms for this protection are poorly understood. Caveolae,
sarcolemmal invaginations, and caveolins, scaffolding proteins in caveolae, localize molecules involved in cardiac
protection. We tested the hypothesis that caveolae and caveolins are essential for exendin-4 induced cardiac
protection using in vitro and in vivo studies in control and caveolin-3 (Cav-3) knockout mice (Cav-3 KO).
Methods: Myocytes were treated with exendin-4 and then incubated with methyl-β-cyclodextrin (MβCD) to disrupt
caveolae formation. This was then followed by simulated ischemia/reperfusion (SI/R). In addition, cardiac protection
in vivo was assessed by measuring infarct size and cardiac troponin levels.
Results: Exendin-4 protected cardiac myocytes (CM) from SI/R [35.6 ± 12.6% vs. 64.4 ± 18.0% cell death, P = 0.034]
and apoptosis but this protection was abolished by MβCD (71.8 ± 10.8% cell death, P = 0.004). Furthermore, Cav-3/
GLP-1R co-localization was observed and membrane fractionation by sucrose density gradient centrifugation of CM
treated with MβCD + exendin-4 revealed that buoyant (caveolae enriched) fractions decreased Cav-3 compared to CM
treated with exendin-4 exclusively. Furthermore, exendin-4 induced a reduction in infarct size and cardiac troponin
relative to control (infarct size: 25.1 ± 8.2% vs. 41.4 ± 4.1%, P < 0.001; troponin: 36.9 ± 14.2 vs. 101.1 ± 22.3 ng/ml,
P < 0.001). However, exendin-4 induced cardiac protection was abolished in Cav-3 KO mice (infarct size: 43.0 ± 6.4%,
P < 0.001; troponin: 96.8 ± 26.6 ng/ml, P = 0.001).
Conclusions: We conclude that caveolae and caveolin-3 are critical for exendin-4 induced protection of the heart
from ischemia/reperfusion injury.
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Glucagon-like peptide-1 (GLP-1) is an intestinal hormone
secreted in a nutrient-dependent manner that stimulates
insulin secretion and inhibits glucagon secretion and gas-
tric emptying, resulting in reduced post-prandial hypergly-
cemia [1]. GLP-1 acts upon the GLP-1 receptor (GLP-1R),
which belongs to the family of G-protein-coupled receptor
(GPCRs) [2]. This receptor is abundantly expressed in the
gastrointestinal tract, but has also been detected in the
central nervous system, heart, vascular smooth muscle
cells, endothelial cells, and macrophages [3,4]. Recently,* Correspondence: tsutsumi@tokushima-u.ac.jp
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unless otherwise stated.GLP-1 has been shown to reduce an infarct size in both
in vitro and in vivo animal models of cardiac ischemia/
reperfusion injury [5-7] and exendin-4 (Ex-4), an exogen-
ous GLP-1R agonist isolated form the Gila monster lizard
[8], has reported to have very similar effects [4,9,10].
Caveolae are small flask-like invaginations of sarcolemmal
membrane that are enriched in lipids. Caveolin-3 (Cav-3)
is the principal protein component of caveolae and can
interact with a number of signaling molecules includ-
ing G protein, receptor tyrosine kinases, and GPCRs
via caveolin-binding motif [11-13]. In our previous
studies, we have shown that both caveolae and Cav-3
were essential in cardiac protection against ischemia/
reperfusion in the animal model [14-17]. However,
studies addressing the plasma-membrane localizational Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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olae and Cav-3 on GLP-1-induced cardiac protection
has not been investigated. Therefore, we hypothesized
that both caveolae and Cav-3 are a critical component
of GLP-1-induced cardiac protection and that coordination
of protective signaling is dependent on the co-localization
of Cav-3 and GLP-1R.
Material and methods
All animals were treated in compliance with the Guidelines
for Proper Conduct of Animal Experiment and Related
Activities (Ministry of Education, Culture, Sports, Science
and Technology of Japan) and the protocols, which was
assigned to ARRIVE guidelines [18], approved by the Animal
Care and Use Committee at the University of Tokushima.
Male Wistar rats (12–14 weeks old, 250–300 g body weight)
and male C57BL/6 mice (8–10 weeks old, 21–25 g body
weight) were purchased from Japan SLC, and Cav-3 KO
mice (8–10 weeks old, 21–25 g body weight) were created
as reported previously [19]. The animals were kept on a
12 hour light–dark cycle in a temperature and humidity-
controlled room, and had ad lib access to food and water.
Preparation of Cardiac Myocytes (CM)
CM were isolated from adult male Wistar rats as de-
scribed [20,21]. In brief, hearts were retrograde perfused
on a Langendorff apparatus and digested with collagenase
(Worthington). Myocytes were plated in Medium 199
(4% fetal bovine serum and 1% penicillin/streptomycin)
on laminin (2 μg/cm2)-coated plates for 1 h. Plating
media was changed to serum-free media (1% bovine
serum albumin) to remove non-myocytes and CM were
incubated for 24 h at 37°C in 5% CO2.
Simulated ischemia/reperfusion (SI/R) in isolated
cardiac myocytes
CM were plated on laminin-coated 12-well plates, and
simulated ischemia was induced by replacing the air
content with a 95% N2 and 5% CO2 gas mixture at 2 L/min
in a chamber and by replacing the media to glucose-free
media for 60 min. This was then followed by 60 min of
“reperfusion” by replacing the media with normal main-
tenance media and by incubating the cells with 21% O2
and 5% CO2 [16]. CM were exposed to 0.3 nM or 3.0
nM Ex-4, a GLP-1R agonist, for 1 h prior to SI/R. Cell
death was quantified by counting trypan blue-stained
cells with results expressed as a percentage of total cells
counted. Cells were counted (3 random fields per well)
using ImageJ software to determine percent cell death.
To determine the impact of caveolae on cardiac protection,
methyl-β-cyclodextrin (MβCD) was used as described
[16]. CM were incubated under maintenance media
(control conditions) or in the presence of MβCD
(1 mM) for 1 h before SI/R.Depolarization of the mitochondrial membrane
To analyze mitochondrial membrane potential, we used the
JC-1 dye (MitoPT JC-1, ImmunoChemistry Technologies,
Bloomington, MN), which shifts the fluorescence emission
from red (580 nm) to green (488 nm) as mitochondrial
membrane is depolarized. After SI/R, as described above,
myocytes were incubated with JC-1 for 20 min at 37°C, and
cellular fluorescence was determined by a fluorescence
microscope (Leica TCS NT, Heidelberg, Germany). Data
are assessed by comparing the ratios of red/green.
Gene expression analyses
Total RNA was extracted from CM using RNeasy Plus
Universal Mini Kits (QIAGEN, Valencia, CA). Total
RNA (1 μg) was reverse-transcribed to cDNA in a final
volume of 20 μL using the Primescript RT Reagent kit
(Takara, Shiga, Japan). Real-time polymerase chain
reaction (PCR) was performed in a final volume of
10 μL containing 50 ng of the cDNA template and
primers using a StepOnePlus Real-Time PCR System
(Life Technologies, Carlsbad, CA). To determine the
effect on apoptosis gene expression, we measured the
expression of the BH3-interacting domain death agonist
(BID), Bcl-2-associated death promoter (BAD), Caspase-3,
Caspase-8, and Caspase-9, and Bcl-2 associated X protein
(BAX) genes. To determine the effect on anti-apoptosis gene
expression, we measured the expression of the B-cell lymph-
oma 2 (BCL-2) and inhibitor of apoptosis 1 (IAP-1) genes.
Immunofluorescence
CM were fixed with paraformaldehyde, incubated with
100 mM glycine, permeabilized in 0.1% buffered Triton
X-100, and blocked with 1% bovine serum albumin,
phosphate-buffered saline, and 0.05% Tween. Samples
were then incubated with primary antibody (GLP-1R and
caveolins-3, Santa Cruz Biotechnology, Santa Cruz, CA)
(1:100) in 1% bovine serum albumin, phosphate-buffered
saline, and 0.05% Tween for 24 h. Excess antibody was
removed, and samples were incubated with fluorescein
Alexa-conjugated secondary antibodies (1:250) for 1 h. To
remove excess secondary antibody, samples were washed
with phosphate-buffered saline/0.1% Tween and samples
were mounted in UltraCruz (Santa Cruz Bioctechnology)
for microscopy imaging. Fluorescent images of cell sections
excited at 488 and 560 nm were captured using a confocal
laser scanning microscope (Leica TCS NT, Heidelberg,
Germany) equipped with an argon-krypton laser
source. Images were taken at 400 × magnification and
were assessed quantitatively by Image-Pro Plus (Media
Cybernetics, Silver Spring, MD).
Sucrose density fractionation
Whole left ventricles or myocytes were used for sucrose
density membrane fractions as reported previously [22].
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1 ml of 80% sucrose in 25 mM MES and 150 mM NaCl
(MES buffered saline, MBS, pH 6.5) to form 40% sucrose
and loaded at the bottom of an ultracentrifuge tube. A
discontinuous sucrose gradient was generated by layer-
ing 6 ml of 35% sucrose prepared in MBS followed by
4 ml of 5% sucrose in MBS. The gradient was centrifuged
at 175,000 g using a P70AT2 rotor (Hitachi Koki Co.) for
3 h at 4°C. After centrifugation, samples were removed in
1 ml aliquots to yield 12 fractions. We defined fraction 4–6
as buoyant membrane fractions enriched in caveolae and
proteins associated with caveolae. Fraction 9–12 were
defined as nonbuoyant fractions.
Immunoprecipitation
Immunoprecipitation was performed using Protein A
Sepharose CL-4B (GE Healthcare) as described previously
[23]. Buoyant fraction samples were incubated with
primary antibody (GLP-1R and caveolins-3, Santa Cruz
Biotechnology) for 3 h at 4°C, immune-precipitated
overnight with protein-agarose at 4°C, and then centri-
fuged for 5 min at 13,000 g. Protein-agarose pellets
were washed 3 times. Wash buffer was removed and
sample buffer was added, and then boiled for 5 min at
95°C for immunoblotting.
Immunoblot analysis
Proteins were separated by SDS-PAGE 10% polyacrylamide
precast gels (Bio-Rad Laboratories) and transferred to
a polyvinylidene diflouride membrane by electroelution.
Membranes were blocked in PBS containing 2.0% nonfat
dry milk and incubated with primary antibody overnight
(GLP-1R and caveolins-3, Santa Cruz Biotechnology;
GAPDH, Santa Cruz Biotechnology and Cell Signaling
Technology) and at 4°C. Bound primary antibodies
were visualized using secondary antibodies (Santa Cruz
Biotechnology) conjugated with horseradish peroxidase
from Santa Cruz Biotechnology and ECL reagent from GE
Healthcare [24]. All displayed bands migrated at the ap-
propriate size, as determined by comparison to molecular
weight standards (Santa Cruz Biotechnology).
Ischemia/reperfusion protocol and experimental groups
C57BL/6 mice and Cav-3 knockout (Cav-3 KO) micewere
anesthetized with pentobarbital sodium (80 mg/kg ip) and
mechanically ventilated by using a pressure-controlled
ventilator (TOPO Ventilator, Kent Scientific) as described
before [25]. Core temperature was maintained with a heat-
ing pad and ECG leads were placed to record heart rate.
The hemodynamic effects were measured through the
right carotid artery cannulation with a 1.4 F Mikro-tip
pressure transducer (Model SPR-671, Millar Instruments),
which was connected to an amplifier (Model TC-510, Millar
Instruments) for determination of heart rate, arterial bloodpressure, and rate pressure product as previous before [26].
After thoracotomy, baseline was established, and mice were
randomly assigned to experimental protocols. Lethal ische-
mia was produced by occluding the left coronary artery with
a 7–0 silk suture on a taper BV-1 needle (Ethicon) for
30 min. After 30 min of occlusion, the ligature was re-
leased and the heart was reperfused for 2 h. After reper-
fusion, mice were heparinized, and the coronary artery
was again occluded. The area at risk (AAR) was determined
by staining with 1% Evans blue (Sigma). The heart was im-
mediately excised and placed into 1% agarose and allowed
to harden. Once hardened, the heart was cut into 1.0-mm
slices (McIlwain tissue chopper; Brinkmann Instruments).
Each slice of left ventricle (LV) was then counterstained with
2,3,5,-triphenyltetrazolium chloride (Sigma). After overnight
storage in 10% formaldehyde, slices were weighed and visu-
alized under a microscope (SZ61-TR, Olympus) equipped
with a charge coupled device camera (DXM 1200 F, Nikon).
The images were analyzed (Image-Pro Plus, Media
Cybernetics), and AAR and infarct size (IS) was deter-
mined by planimetry as previously described [27,28].
Cardiac troponin I levels in the serum were measured
using a High Sensitivity Mouse Cardiac Troponin-I
ELISA Kit (Life Diagnostics).
Statistical analysis
Statistical analyses were performed by one-way and two-way
ANOVA for repeated measures, followed by Bonferroni
post-hoc test. All data are expressed as mean ± SD.
Statistical significance was defined as P < 0.05.
Results
Experimental animals
The animals’ health status was monitored throughout the
experiments by a health surveillance program. A total of
98 animals were used in the experiments described here
(35 animals for in vitro simulated ischemia/reperfusion,
23 for immunofluorescence and immunoblot analyses,
and 40 for in vivo ischemia/reperfusion experiments).
Five mice died shortly after ischemia/reperfusion be-
cause of fatal cardiac arrhythmia in the in vivo experi-
ments (control, 1; Ex-4 administration, 2; Cav-3 KO
control, 1; Cav-3 KO Ex-4 administration, 1).
Exendin-4 induces cardiac protection in CM
CM were administered with various concentration of Ex-4
and then SI/R (Figure 1A). Administration of 0.3 nM and 3.0
nM Ex-4 before SI/R decreased cell death when compared
to SI/R alone (47.4 ± 9.9%, and 35.6 ± 12.6% and 64.4 ± 18.0%
cell death, respectively, n = 5 per each groups; Figure 1B).
MβCD abolish exendin-4 induced cardiac protection
CM were incubated with 1% BSA with 0.1% penicillin/
streptomycin (Control) or in control media along with
Figure 1 Effects of exendin-4 on simulated ischemia/reperfusion (SI/R) of cardiac myocytes. (A) Cardiac myocytes were rod-shaped and
treated with various concentration of exendin-4 prior to exposure to SI/R. (B) Cell death was determined by trypan blue staining. Optimal protection
was observed at 3.0 nM exendin-4. Group sizes are indicated on the individual bars in parentheses.
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(Figure 2A). In the present study, the protective effect of
Ex-4 was abolished in CM with MβCD (35.6 ± 12.6% [n = 4]
and 71.8 ± 10.8% [n = 5] cell death, respectively; P = 0.004).
Additionally, we observed no significant increase in basal
cell death with the various treatments (Figure 2B).
To test whether Ex-4 inhibited apoptosis by modifying the
mitochondrial membrane potential during reperfusion injury,
we measured a membrane potential-sensitive dye, 5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenzamidazolocarbocyanin
iodide (JC-1). As shown in Figure 2C, Ex-4 inhibited
reduction of mitochondrial membrane potential that oc-
curred in the re-oxygenated cells expressing SI/R suggest-
ing inhibition of apoptosis. This was further confirmed as
Ex-4 decreased pro-apoptic and increased anti-apoptotic
gene expression (Figure 2D; n = 4 per each groups).
Co-localization between GLP-1R and Cav-3, and MβCD
alter caveolins expression
Immunofluorescence microscopy showed that Cav-3
co-localizes with GLP-1R on the surface of the CM(Figure 3A). Co-immunoprecipitation experiments using
cardiac lysates and antibodies to Cav-3 and GLP-1R pro-
vided further evidence for the interaction of these proteins
(Figure 3B). Expression of Cav-3 in buoyant caveolar
fractions (fractions 4–6) was significantly increased after
administration of Ex-4 as compared with control mice,
and Ex-4 induced migration of Cav-3 from non-buoyant
to buoyant fraction was eliminated by MβCD (Figure 4).
Caveolin-3 is required for exendin-4 induced
cardiac protection
To assess the role of Cav-3 in the protection from ischemia/
reperfusion injury, we treated C57BL/6 wild-type mice or
Cav-3 KO mice with Ex-4 administration, and then exposed
the mice to ischemia/reperfusion (Figure 5A). We found
no significant differences between groups in pre-occlusion
heart rate, blood pressure, or rate pressure product with
and without Ex-4 (Table 1). The ability of Ex-4 to protect
from ischemia/reperfusion injury was abolished in
Cav-3 KO mice compared to wild-type animals (43.0 ± 6.4%
[n = 8] and 25.1 ± 8.2% [n = 7] IS/AAR, P < 0.001) even
Figure 2 In vitro assessment of the role of caveolae in exendin-4 (Ex-4) induced cardiac protection. (A) Summary illustration of in vitro
experimental groups. (B) Cardiac myocytes exposed to simulated ischemia/reperfusion (SI/R) were exposed to experimental procedures outlined
in A. Cell death was determined by trypan blue staining. Cardiac myocytes under control conditions (Control) had minimal cell death.
Methyl-β-cyclodextrin (MβCD) abolished the Ex-4 induced cardiac protection effect. Group sizes are indicated on the individual bars in parentheses.
(C) Apoptotic changes were measured by investigating mitochondrial membrane potential using JC-1 after SI/R. The excitation rate (red/green)
indicates changes within the mitochondrial membrane potential. *P < 0.001 vs. SI/R, SIR + Ex-4, SI/R with MβCD, and SI/R + Ex-4 with MβCD. #P < 0.05
vs. Control, SI/R + Ex-4, and Control with MβCD. n = 4 per each group. (D) Real-time polymerase chain reaction analysis of pro-apoptotic and
anti-apoptotic gene expression after re-oxygenation. n = 4 per each group.
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(Figure 5B). Cardiac troponin I (cTnI) levels were signifi-
cantly attenuated by Ex-4 treatment in wild-type mice com-
pared to control mice subjected to ischemia/reperfusion
(36.9 ± 14.2 and 101.1 ± 22.3 ng/ml, P < 0.001); however,
GLP-1 failed to reduce cTnI in Cav-3 KO mice and alevel similar to control Cav-3 KO mice was observed
(103.4 ± 38.4 and 96.8 ± 26.6 ng/ml, Figure 5C).
Discussion
In the current study, treatment with MβCD, an agent
that has been shown to decrease the number of caveolae,
Figure 3 Glucagon-like peptide-1 receptor (GLP-1R) localization
with caveolins or caveolae. (A) Immunofluorescence analysis of
the expression and colocalization of caveolin-3 (Cav-3) and GLP-1R
in cardiac myocytes. Fluorescent secondary antibodies were used to
determine Cav-3 (green) and GLP-1R (red) localization, and strong
colocalization (merged images, yellow) were observed on the cell
surface membrane. Bar length = 10 μm. (B) The colocalization was
confirmed by immunoprecipitation (IP). Immunoblot (IB) analysis
detected Cav-3 and GLP-1R in Cav-3 and GLP-1R IP of cell lysates.
Supernatants (SUP) from which the immunoprecipitates were
generated were stained for GAPDH as loading controls.
Figure 4 Lysed and fractionated hearts on sucrose density
gradient. Fractions were collected and probed for caveolin-3
(Cav-3). We defined fractions 4–6 as buoyant membrane fractions
enriched in caveolae and proteins associated with caveolae; fractions
9–12 were defined as nonbuoyant fractions, noncaveolar membranes.
Fraction 7–8 were considered a transition zone and were not analyzed.
Significant localization of Cav-3 in buoyant fractions was observed
in the groups treated with exendin-4 (Ex-4), whereas control and
methyl-β-cyclodextrin (MβCD)-treated with Ex-4 cells showed no
effects on Cav-3 localization. Group sizes are indicated on the
individual bars in parentheses.
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duced cardiac protection in in vitro models. Additionally,
consistent with these findings, we observed that Ex-4
induced cardiac protection cannot be elicited in Cav-3
KO mice, indicating that the presence of caveolae
(dependent on Cav-3 expression) is essential for myocardial
protection in the in vivo mouse models. This is the first
study to investigate the role of caveolins or caveolae in Ex-4
induced cardiac protection.
GLP-1 cardioprotection
Nutrient-responsive intestinal hormones including GLP-1
are rapidly metabolized by enzyme dipeptidyl-peptidase-4
(DPP-4) to generate an N-terminally truncated metabolite
GLP-1 (9–36) [1,29]. Previous studies have demonstrated
that the cardioprotective effect of exogenous GLP-1
were attributed to GLP-1R activation and subsequent
recruitment of numerous intracellular signaling path-
ways involving protein kinase B, extracellular regulated
kinases, p70S6K, and 5’ adenosine monophosphate-activated
protein kinase as well as downstream phosphorylation
and inhibition of the pro-apoptotic protein BAD [5,6,30].
Hausenloy et al. also showed that chronic treatment with
DPP-4 inhibitors reduce infarct size via the GLP-1R-
protein kinase A pathway, in a glucose dependent manner
in vivo rat models and confirmed the cardioprotective
action of the endogenous intact GLP-1 on ischemia/
reperfusion injury [31]. Moreover, Bao et al. [32] revealedthat the long acting GLP-1R agonist could provide
more sustained cardioprotective effect in the setting of
acute myocardial ischemia/reperfusion injury than the
short-acting Ex-4.
GLP-1 and the caveolin-dependent pathway
Caveolae, cholesterol and sphingolipid enriched invagi-
nations of plasma membrane play a role physiological
functions and vital to cardiac protective mechanisms.
Caveolae and caveolins have been shown to play a fun-
damental role in the phenomenon of myocardial pro-
tection against ischemia/reperfusion injury [11-13]. In
the present study, we investigated that wild-type mice
Figure 5 Caveolin-3 expression and reduction in infarct size.
Mice underwent 30-min coronary artery occlusion followed by 2-h
reperfusion after 24-h recovery from pretreatment with oxygen
(Control) or exendin-4 (Ex-4) in wild-type and caveolin-3 knockout
(Cav-3 KO) mice. (A) In vivo Ex-4 induced cardiac protection protocol.
(B) Area at risk was calculated as a percentage of the left ventricle
and revealed no significant differences between all groups. Ex-4 induced
cardiac protection was abolished Cav-3 KO mice, as shown by no
significant decrease in percent infarct size / area at risk when
compared to control Cav-3 KO; however, a significant decrease in
infarct size was observed between wild-type Ex-4 and Cav-3 KO
Ex-4. (C) Cardiac troponin I, a marker of myocardial damage also
revealed a significant decrease in Ex-4 treated control mice, but no effect
in Cav-3 KO mice. Group sizes are indicated on the individual bars in
parentheses. *P < 0.001 compared with Cav-3 KO pretreated with Ex-4.
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ischemia/reperfusion injury in vivo, whereas Cav-3 KO
mice were not. In addition, Ex-4 protected isolated CM
from hypoxia-induced cell death in vitro and had profound
effects on membrane microdomains of CM. Our previous
studies also revealed that Cav-3 KO mice, which decrease
the number of myocardial caveolae, lose the ability to
undergo cardioprotection from ischemia/reperfusioninjury both in vitro and in vivo models [14-17]. Although
there has been little evidence regarding the relationship
between caveolae, caveolins and GLP-1R within the heart,
other organ systems including human embryonic kidney
(HEK) 293 cells and pancreatic β cells [33,34]. Syme et al.
demonstrated that GLP-1 receptor interacts with Cav-1 in
an association that is necessary for receptor trafficking
to the cell membrane and signaling activity in HEK 293
cells [33]. Furthermore, Yang et al. demonstrated that
activation peroxisome proliferator-activated receptor
β/σ protects pancreatic β cells from apoptosis by upreg-
ulating the expression of GLP-1R, and sterol regulatory
element binding protein-1c/Cav-1 pathway regulates GLP-
1R expression [34].
In the present study, we showed that that GLP-1R
interacted with Cav-3 and that the administration of
Ex-4 led to cardiac protection. Caveolins can interact
with a series of signaling molecules, including GPCRs
via caveolin-binding motifs and may act as a molecu-
lar chaperone for GPCRs [12,13]. Overexpression of a
dominant-negative form of Cav-1 or mutations within
the Cav-1 binding domain of the GLP-1R attenuated
GLP-1 binding and GLP-1R expression at the membrane
[33]. Collectively, these data implicate that caveolae and
caveolins are essential for GLP-1 induced cardiac protec-
tion by mediating the GLP-1R.
Hemodynamic effects of GLP-1
GLP-1 has been shown to increase blood pressure and
heart rate in rats [35,36] although others failed to demon-
strate any hemodynamic changes in the porcine models
[37,38] and human studies [39-42]. In addition, Bose et al.
investigated that the effects of GLP-1 infusion in rats sub-
jected to 30 min ischemia and 120 min of reperfusion and
observed that GLP-1 had no hemodynamic differences in
their in vivo and ex vivo experimental models [5,30,43].
The hemodynamic effects of Ex-4 were also assessed in
the animal models, in which dose-dependent increases in
mean arterial pressure and heart rate were noted in rats
[44]. In our in vivo studies, however, there were not any
hemodynamic changes among the groups at the pre-
occlusion time. This may be due to the dose and the tim-
ing of administration, Gardiner et al. showed that at a
dose of 25 ng/kg i.v., Ex-4 had little effect, but at higher
concentrations (250 ng/kg) significant tachycardia and
pressor effects were noted for 60 min [44]. As the dose
and time period used for cardiac protection in mice are
not known, we selected the dosage and time of adminis-
tration for Ex-4 based on the reports of Gardiner et al.
to prevent any hemodynamic differences during pre-
occlusion (250 ng/kg i.v. at 60 min before occlusion)
[44]. Furthermore, GLP-1 has been shown to have cen-
tral nervous effects on the control of blood pressure
and heart rate [45]; however, this mechanism can be
Table 1 Hemodynamics
Baseline Pre-occlusion Ischemia Reperfusion
30 min 2 h
Heart rate, beats · min−1
WT Control 430 ± 26 426 ± 26 383 ± 39*# 363 ± 26*#
WT Ex-4 432 ± 16 413 ± 41 402 ± 16 398 ± 9
Cav-3 KO Control 413 ± 27 415 ± 25 383 ± 25 381 ± 32
Cav-3 KO Ex-4 416 ± 28 419 ± 26 376 ± 39 357 ± 36*#
Mean arterial pressure, mmHg
WT Control 75 ± 6 75 ± 6 70 ± 6 65 ± 10*#
WT Ex-4 78 ± 5 75 ± 5 72 ± 7 70 ± 8
Cav-3 KO Control 77 ± 4 75 ± 4 71 ± 3* 65 ± 6*#
Cav-3 KO Ex-4 76 ± 5 75 ± 5 70 ± 3 66 ± 5*#
Rate-Pressure Product, beats · min−1 · mmHg · 103
WT Control 32.0 ± 3.3 32.0 ± 1.4 26.7 ± 3.5*# 23.7 ± 4.7*#
WT Ex-4 33.6 ± 2.7 31.2 ± 4.1 29.2 ± 3.5 28.0 ± 3.6*
Cav-3 KO Control 31.9 ± 2.2 31.1 ± 2.6 27.0 ± 2.3*# 25.0 ± 3.5*#
Cav-3 KO Ex-4 31.5 ± 3.7 31.5 ± 3.2 26.4 ± 3.5*# 23.4 ± 2.6*#
Data are mean ± SD. Wild-type (WT) or caveolins-3 knockout (Cav-3 KO) mice were randomly exposed to exendin-4 (Ex-4).
*Significantly (P < 0.05) different from baseline (intragroup comparison).
#Significantly (P < 0.05) different from pre-occlusion (intragroup comparison).
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models, we used 3.0 nM Ex-4 concentration, consistent
with previous study by Ban et al. in which 3.0 nM Ex-4
protect against after ischemia/reperfusion in isolated
mouse hearts [4,10].
Study limitations
There are several limitations in the present study. First,
we evaluated the GLP-1R dependent effects of Ex-4 in
experiments that investigated ischemia/reperfusion injury.
Recent studies suggest that GLP-1 (9–36), the metabolite
that is generated by DPP-4 and 1000-fold lower affinity
to GLP-1R [46], also improve LV contractile function
and post-ischemic myocardial injury [47]. Furthermore,
GLP-1R knockout mice have lower heart rate and blood
pressure with an increase in cardiac mass and GLP-1
has been shown to protect perfused hearts from rodents
lacking GLP-1R from ischemia [4]. These findings suggest
that GLP-1 and its metabolite GLP-1 (9–36) may be
capable of exerting GLP-1 receptor-independent path-
ways on the cardiovascular system [10]. Second, Cav-3
KO mice have a variety of deleterious phenotypes (i.e.,
muscle degeneration, insulin resistance, and progressive
cardiomyopathy with age) that may affect outcome after
ischemia/reperfusion injury [19,48,49].
Clinical implications
As a regulator of glucose homeostasis, an exogenous
GLP-1 analogue or potentiating endogenous GLP-1 by
DPP-4 inhibitors show promise for the treatment oftype 2 diabetes mellitus (T2DM) associated with cardiovas-
cular disease. Moreover, there have been several clinical
trials using GLP-1 as a therapy for cardiovascular disease in
human subjects. Exenatide, an exogenous GLP-1 analogue,
was found to be more beneficial than the other current
regimens (DPP-4 inhibitors, insulin or tiazolidinediones), in
reaching therapeutic goals recommended by the American
Diabetes Association in the treatment of T2DM, which is
also promising in the reduction of other co-morbidities
such as cardiovascular risk [50]. Lonborg et al. [51] has
shown that exenatide resulted in an increased salvage index
among ST-segment elevation myocardial infarction patients
with hyperglycemia and normoglycemia. Interestingly,
endogenous circulating GLP-1 level was found to be
increased in patients with high cardiovascular risk, sug-
gesting it represents a contra-regulatory response in states
of increased metabolic risk [52].Conclusions
In conclusion, the current results demonstrate that GLP-1R
co-localized with caveolae and caveolins-3 are essential
for the cardiac protection induced by exendin-4 from
ischemia/reperfusion injury.
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